NetworkNewsBreaks – Pressure BioSciences (PBIO) Locks In Final System Design, Begins Production of Alpha Unit
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, has reached what it calls as a critical milestone. The company announced the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology(TM)-based nanoemulsification system. In addition, PBIO has begun initial commercial system development of the system. Once the alpha unit has been tested and approved, the company will begin building an additional 15 ready-for-sale systems. This strategy aligns with PBIO’s objective of shipping the BaroShear K45 UST System in early 2021. Based on a patented UST platform, BaroShear K45 is a proprietary nanoemulsification system that resolves a significant challenge faced by manufacturers of biotherapeutic drugs, nutraceuticals (including hemp-derived CBD products) and other products containing oil-based active ingredients: the difficulty humans have in accessing and absorbing active ingredients within oil drops. Poor water solubility makes designing and delivering proper dosing problematic. “The data generated over the past 18 months with both our bench-top and floor model prototypes have validated the ability of our revolutionary UST platform to create high quality, highly stable nanoemulsions of oil and water,” said PBIO president and CEO Richard T. Schumacher in the press release. “These exciting results support our belief that our revolutionary UST platform can help a diverse range of customers develop a vast array of new and beneficial products across many multi-million and multi-billion dollar markets, including hemp-derived CBD and other nutraceuticals, cosmetics and topical treatments, food and beverages , and biotherapeutic drugs – such as in the example of Prednisone above. We look forward with excitement to the upcoming commercial release of our revolutionary UST-based BaroShear K45 nanoemulsification system by early (Q1/Q2) 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, has reached what it calls as a critical milestone. The company announced the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology(TM)-based nanoemulsification system. In addition, PBIO has begun initial commercial system development of the system. Once the alpha unit has been tested and approved, the company will begin building an additional 15 ready-for-sale systems. This strategy aligns with PBIO’s objective of shipping the BaroShear K45 UST System in early 2021. Based on a patented UST platform, BaroShear K45 is a proprietary nanoemulsification system that resolves a significant challenge faced by manufacturers of biotherapeutic drugs, nutraceuticals (including hemp-derived CBD products) and other products containing oil-based active ingredients: the difficulty humans have in accessing and absorbing active ingredients within oil drops. Poor water solubility makes designing and delivering proper dosing problematic. “The data generated over the past 18 months with both our bench-top and floor model prototypes have validated the ability of our revolutionary UST platform to create high quality, highly stable nanoemulsions of oil and water,” said PBIO president and CEO Richard T. Schumacher in the press release. “These exciting results support our belief that our revolutionary UST platform can help a diverse range of customers develop a vast array of new and beneficial products across many multi-million and multi-billion dollar markets, including hemp-derived CBD and other nutraceuticals, cosmetics and topical treatments, food and beverages , and biotherapeutic drugs – such as in the example of Prednisone above. We look forward with excitement to the upcoming commercial release of our revolutionary UST-based BaroShear K45 nanoemulsification system by early (Q1/Q2) 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
